Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of MK-2870 + pembrolizumab versus physician's choice adjuvant therapy in residual TNBC after neoadjuvant pembrolizumab-based chemotherapy
MOH_2024-05-26_013433Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan and pembrolizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Merck & Co. Primary endpoint: Invasive disease-free survival. Planned start May 2024; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2024-05-26_013433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-26_013433.